Norway vs Singapore: The number of people with susceptibility test result for rifampicin
Norway
98.57
in 2021
Singapore
98.69
in 2021
Norway rank
36th
Singapore rank
35th
The number of people with susceptibility test result for rifampicin over time
- Norway
- Singapore
How they compare
Singapore currently reports 98.69 against 98.57 in Norway, a difference of 0.12.
The two have swapped places 3 times across 5 shared years of data; in 2017 it was Norway ahead.
Norway ranks 36th and Singapore ranks 35th of 146 countries.
Across the 2 decades both report, Norway averaged higher in 1 and Singapore in 1.
Head to head by decade
| Decade | Norway | Singapore | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 95.09 | 97.43 | 2.34 | Singapore |
| 2020s | 98.68 | 98.42 | 0.2541 | Norway |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Norway or Singapore?
- Singapore, at 98.69 against 98.57 in Norway as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Norway and Singapore?
- 0.12, with Singapore ahead.
- How many years of comparable data are there for Norway and Singapore?
- 5 years are reported by both, from 2017 to 2021.
- How do Norway and Singapore rank globally for the number of people with susceptibility test result for rifampicin?
- Norway ranks 36th and Singapore ranks 35th of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.